GSA Capital Partners’s Xilio Therapeutics XLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$151K Buy
16,673
+3,083
+23% +$27.9K 0.01% 1654
2026
Q2
$130K Sell
13,590
-3,356
-20% -$28K 0.01% 1601
2026
Q1
$143K Buy
16,946
+6,377
+60% +$52.2K 0.01% 1517
2025
Q4
$95K Buy
+10,569
New +$111K 0.01% 1535

Other funds holding XLO

GSA Capital Partners's XLO Position: Q3 2026 in Review

GSA Capital Partners increased its Xilio Therapeutics (XLO) stake by 23% in Q3 2026, buying an estimated $27.9K and bringing the position to 16,673 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #1654.

GSA Capital Partners first reported a position in XLO in Q4 2025 and has held it in 4 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

  • GSA Capital Partners held 16,673 shares of Xilio Therapeutics worth $151K as of Q3 2026.
  • GSA Capital Partners bought 3,083 Xilio Therapeutics shares in Q3 2026, an estimated $27.9K.
  • Xilio Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1654 holding.
  • GSA Capital Partners first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.